Supporting Figures S1-S4 from Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer
Year: 2023
Type: other
Abstract: S1: SARDs inhibit AR mutant activity. S2: UT-155-dependent degradation is selective to the AR. S3: UT-155 degrades wildtype and Y267 phospho mutant ARs. S4. UT-155 inhibits AR ABCD and AR-V7 induced activity.
Authors: Suriyan Ponnusamy, Christopher C. Coss, Thirumagal Thiyagarajan, Kate Watts, Dong-Jin Hwang, Yali He, Luke A. Selth, Iain J. McEwan, Charles B. Duke, Jayaprakash Pagadala, Geetika Singh, Robert W. Wake, Christopher Ledbetter, Wayne D. Tilley, Tudor Moldoveanu, James T. Dalton, Duane D. Miller, Ramesh Narayanan
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361876193